Stock Events

Stock Events

Search...

Esperion Therapeutics

$2.07

54

+$0+0% Wednesday 17:51

Statistics

Day High

2.12

Day Low

2.05

52W High

3.32

52W Low

0.71

Volume

21,383

Avg. Volume

26,659

Mkt Cap

-

P/E Ratio

-

Dividend Yield

-

Dividend

-

Upcoming

Earnings

5NovExpected

Q1 2023

Q2 2023

Q3 2023

Q4 2023

Q1 2024

Q2 2024

Next

-0.79

-0.41

-0.04

0.34

Expected EPS

-0.165

Actual EPS

N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 0IIM.LSE. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Amgen produces Repatha, a PCSK9 inhibitor that competes directly with Esperion's cholesterol-lowering drugs.

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, in collaboration with Sanofi, markets Praluent, another PCSK9 inhibitor, directly competing in the cholesterol management market.

Sanofi, partnering with Regeneron, is involved in the marketing of Praluent, making it a direct competitor in the cholesterol-lowering space.

Merck & Co. offers cholesterol management drugs that, while not PCSK9 inhibitors, still compete in the broader market for cholesterol treatment solutions.

AstraZeneca provides Crestor, a statin, which is part of the broader cholesterol management market, competing for similar patient populations.

Pfizer is known for its Lipitor, one of the best-selling cholesterol-lowering drugs, competing in the same therapeutic area.

Novartis has a portfolio of cardiovascular drugs that, while not directly competing as PCSK9 inhibitors, still vie for market share in the broader cardiovascular treatment space.

AbbVie, through its acquisition of Allergan, has expanded its portfolio into cardiovascular diseases, indirectly competing with Esperion.

GlaxoSmithKline offers a range of cardiovascular drugs, competing in the broader market for heart disease treatments.

Eli Lilly and Company, while not a direct competitor in the PCSK9 space, has a growing interest in cardiovascular diseases, potentially competing for the same patient demographic.

About

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9 inhibitor program. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

Show more...

CEO

Mr. Sheldon L. Koenig

Employees

218

Country

United States

ISIN

US29664W1053

Listings